 COPENHAGEN, Denmark, Oct. 15, 2021 GLOBE NEWSWIRE -- Ascendis Pharma AS Nasdaq: ASND, today announced the U.S. commercial launch of SKYTROFA lonapegsomatropin-tcgd, its once-weekly treatment for the treatment of pediatric patients one year and older who weigh at least 11.5 kg 25.4 lb and have growth failure due to inadequate secretion of endogenous growth hormone GH. SKYTROFA lonapegsomatropin-tcgd is available by prescription and distributed through a network of specialty pharmacies across the United States. 